另见
Galidesivir
MK-608
NITD008
参考
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. (March 2018). "Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease". mBio. 9 (2). doi:10.1128/mBio.00221-18. PMC 5844999. PMID 29511076.
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS (June 2017). "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses". Science Translational Medicine. 9 (396). doi:10.1126/scitranslmed.aal3653. PMC 5567817. PMID 28659436.
"Coronavirus Vaccine Candidate Eyed for Human Trials by April". 22 January 2020. Retrieved 23 January 2020.
"Experimental Ebola drug 'remdesivir' may help protect against Nipah virus, say scientists". 3 June 2019.
"Scientists Claim Drug Designed to Beat Ebola Also Fights Off Nipah". 2 June 2019.
Preidt R (June 29, 2017). "Experimental Drug Shows Promise Against Dangerous Viruses: Medicine worked in lab tests against germs that cause SARS and MERS infections". Archived from the original on 28 July 2017.
Cihlar T (20 October 2015). "Discovery and Development of GS-5734, a Novel Nucleotide Prodrug with Broad Spectrum Anti-Filovirus Activity". FANG-WHO Workshop, Fort Detrick, MD. Gilead Sciences.
Warren T, Jordan R, Lo M, Soloveva V, Ray A, Bannister R, et al. (Fall 2015). "Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates". Open Forum Infect Dis. 2. doi:10.1093/ofid/ofv130.02.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al. (July 2016). "Late Ebola virus relapse causing meningoencephalitis: a 病例报告". Lancet. 388 (10043): 498–503. doi:10.1016/S0140-6736(16)30386-5. PMC 4967715. PMID 27209148.
"Ebola Treatment Trials Launched In Democratic Republic Of The Congo Amid Outbreak". NPR.org. Retrieved 2019-05-28.
McNeil, Jr., Donald G. (12 August 2019). "A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo". The New York Times. Retrieved 13 August 2019.
Molteni M (12 August 2019). "Ebola is Now Curable. Here's How The New Treatments Work". Wired. Retrieved 13 August 2019.
"Gilead mulls repositioning failed Ebola drug in China virus". Fierce Biotech. Retrieved 31 January 2020.
Joseph, Saumya Sibi; Samuel, Maju (2020-01-31). "Gilead working with China to test Ebola drug as new coronavirus treatment". Thomson Reuters. Archived from the original on 2020-01-31. Retrieved 2020-01-31.